



File Number *EVI*

PERMIT TO IMPORT

THERAPEUTIC SUBSTANCE(S) UNDER REGULATION 5A
OF THE CUSTOMS (PROHIBITED IMPORTS) REGULATIONS

Number

19363

LT

This permit is to be presented to the Collector of Customs at the port of entry

Importer's
Name and
Address

*Medical & Dental Supply Co
Guildford Logistics Battalion
GUILDFORD WA 6055*

Permission is granted to the above named to import into Australia the following therapeutic substance(s) under the above stated Regulations (where applicable the application to import has been subjected to quarantine scrutiny):

*Eighty (80) vials Nalbuphine Hydrochloride injection 10mg/mL
10 mL manufactured by Dupont UK, Weymouth, Dorset, New
Zealand.*

THIS PERMISSION IS SUBJECT TO THE FOLLOWING REQUIREMENTS OR PROHIBITIONS:

1. This permit is a **LIMITED AUTHORITY** for the importation of the above stated quantity (ies) **ONLY**.
2. The importer is required to keep records with respect to the custody, use, disposal or distribution of the above therapeutic substance(s) for a period of three years from the date of importation.

3. *For use in combat zone only. Not for general distribution
in Australia. As this Dept has not evaluated any data for this product
no guarantees of quality, safety or efficacy are given or implied*

THIS PERMISSION IS ALSO SUBJECT TO THE PROHIBITIONS OR REQUIREMENTS SPECIFIED WITH AN 'X' BELOW:

- ☐ for invitro (diagnostic) use **ONLY**.
- ☐ to be labelled '**CAUTION MAY BE INFECTIOUS**'.
- ☐ Australian Radiation Laboratory approval to import also required.
- ☐ for personal use **ONLY** - **NOT** to be distributed for use by other persons or in animals.

- ☐ for delivery into store **ONLY** - distribution may **NOT** take place without permission of the Secretary.
- ☐ for supply to approved users **ONLY**.
- ☐ for laboratory animal use **ONLY**.
- ☐ for veterinary use **ONLY**.
- ☐ **NOT** to be used in animals.

Signature of Authorised Officer for the Secretary

Date

14.8.90.

Further applications to import this/these or any other Therapeutic substance(s) should be made in writing to:
The Drug Evaluation Branch, Therapeutic Goods Administration, P.O. Box 100, WODEN ACT 2606, AUSTRALIA